QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aeon-biopharma-files-for-class-a-common-stock-offering-of-up-to-50m

- SEC Filing

 hc-wainwright--co-maintains-buy-on-aeon-biopharma-lowers-price-target-to-5

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target fro...

 aeon-biopharma-q2-2024-gaap-eps-422-may-not-compare-to-019-estimate

AEON Biopharma (AMEX:AEON) reported quarterly earnings of $4.22 per share which may not compare to estimate of $(0.19) by 2321....

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.

 aeon-biopharma-announces-strategic-resource-reprioritization-and-cost-reduction-plan-aeon-has-reduced-its-workforce-by-55

AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused ...

 hc-wainwright--co-maintains-buy-on-aeon-biopharma-lowers-price-target-to-6

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target fro...

 aeon-biopharma-q1-2024-adj-eps-317-misses-031-estimate

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.17) per share which missed the analyst consensus estimate of $(0.31...

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $18 price target.

 newly-listed-migraine-focused-aeon-biopharma-stock-plunges-on-friday---read-here-why

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION